Physician profile
John J Franklin
NPI 1043360035
$3,464.53
in general payments reported to CMS, 2019-2025
42 companies · $833 in 2025
The $833 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.60 · 2020: $98.83 · 2021: $587 · 2022: $690 · 2023: $666 · 2024: $564 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.25 | 2021-2025 | |
| Pfizer INC. | $322.98 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.72 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $204.19 | 2020-2024 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $171.88 | 2025 | Gemtesa |
| Amgen INC. | $159.85 | 2020-2024 | Evenity, Prolia |
| Gilead Sciences, INC. | $158.76 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.13 | 2022-2025 | |
| Lilly USA, LLC | $153.20 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $135.69 | 2022-2025 | Rexulti |
| Boston Scientific Corporation | $112.12 | 2023-2025 | Watchman Flx, Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $58.01 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $56.03 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $49.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $48.92 | 2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.